Loading
Diabetes Treatment and Management / Advanced Breast Cancer Therapies · Review
Clinical Obesity · August 12, 2026
Well-designed and adequately powered for the question it asks.
This systematic review and meta-analysis found no statistically significant increased risk of depression (RR 1.25, 95% CI 0.95–1.65), anxiety (RR 1.22, 95% CI 0.93–1.60), or suicidal ideation/attempt (RR 1.20, 95% CI 0.90–1.62) with semaglutide compared with comparators or placebo. The authors emphasize that these findings represent absence of detected increased risk in available evidence rather than definitive proof of safety, given substantial heterogeneity and methodological limitations.
Systematic review and meta-analysis. Patients receiving semaglutide for Type 2 diabetes mellitus, obesity or related metabolic conditions; included randomised controlled trials, observational studies, large database analyses and pharmacovigilance disproportionality studies. Intervention: Semaglutide. Compared with: Comparator groups or placebo.
Pooled risk ratio for depression: 1.25 (95% CI: 0.95–1.65; I² = 98%) Pooled risk ratio for anxiety: 1.22 (95% CI: 0.93–1.60; I² = 99%) Pooled risk ratio for suicidal ideation/attempt: 1.20 (95% CI: 0.90–1.62; I² = 92%)
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians should note that current pooled evidence does not demonstrate a statistically significant increased psychiatric risk with semaglutide; however, the substantial heterogeneity and mixed study designs mean this should be interpreted as reassurance rather than definitive safety proof. Continued monitoring and further high-quality studies are warranted.
Rigorous systematic review and meta-analysis with prespecified protocol (PRISMA 2020) across multiple study types and data sources, reporting clear null findings for depression, anxiety, and suicidal ideation with semaglutide, though high heterogeneity limits certainty.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians should note that current pooled evidence does not demonstrate a statistically significant increased psychiatric risk with semaglutide; however, the substantial heterogeneity and mixed study designs mean this should be interpreted as reassurance rather than definitive safety proof. Continued monitoring and further high-quality studies are warranted.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
ABSTRACT Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs), including semaglutide, are widely used for Type 2 diabetes mellitus (T2DM), obesity and related metabolic conditions. Evidence on potential neuropsychiatric effects remains inconsistent. This systematic review and meta‐analysis evaluated depression risk among patients receiving semaglutide. Following PRISMA 2020 guidelines, major biomedical databases, trial registries, pharmacovigilance databases, conference abstracts and grey literature were searched from inception to January 2026. Eligible studies included randomised controlled trials, observational studies, large database analyses and pharmacovigilance disproportionality studies involving patients receiving semaglutide. Risk of bias was assessed using ROBINS‐I and the Newcastle–Ottawa Scale. The pooled risk ratio for depression was 1.25 (95% CI: 0.95–1.65; I 2 = 98%). For anxiety and suicidal ideation/attempt, pooled risk ratios were 1.22 (95% CI: 0.93–1.60; I 2 = 99%) and 1.20 (95% CI: 0.90–1.62; I 2 = 92%), respectively. No statistically significant differences were observed between semaglutide and comparator/placebo groups for outcomes. Pooled estimates did not show a statistically significant increase in depression, anxiety or suicidal ideation/attempt among patients receiving semaglutide compared with comparator groups. However, the certainty of evidence was limited by substantial heterogeneity, risk of bias and reliance on heterogeneous data sources, including spontaneous‐reporting studies. These findings are reassuring but should be interpreted as the absence of a detected increased risk in the available evidence, rather than definitive proof of no psychiatric risk.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.